Search results
Results from the WOW.Com Content Network
The U.S. Food and Drug Administration has approved updated COVID-19 vaccines from Moderna and Pfizer/BioNTech as case counts ... “We are still awaiting more information from the FDA, including ...
The U.S. Food and Drug Administration approved and granted emergency use authorization Thursday for updated COVID-19 vaccines for the upcoming fall and winter season. The FDA said the vaccines ...
National regulatory authorities have granted full or emergency use authorizations for 40 COVID-19 vaccines.. Ten vaccines have been approved for emergency or full use by at least one stringent regulatory authority recognized by the World Health Organization (WHO): Pfizer–BioNTech, Oxford–AstraZeneca, Sinopharm BIBP, Moderna, Janssen, CoronaVac, Covaxin, Novavax, Convidecia, and Sanofi ...
The COVID-19 vaccination campaign in the United States is an ongoing mass immunization campaign for the COVID-19 pandemic in the United States.The Food and Drug Administration (FDA) first granted emergency use authorization to the Pfizer–BioNTech vaccine on December 10, 2020, [7] and mass vaccinations began four days later.
The FDA is reversing course on its COVID vaccine guidance: Rather than having a vaccine that targets the older JN.1 variant, the FDA said fall 2024 vaccines should target a newer strain of the virus.
The Vaccine Adverse Event Reporting System (VAERS) is a United States program for vaccine safety, co-managed by the U.S. Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA). [1]
The U.S. Food and Drug Administration on Friday granted emergency use authorization for an updated version of Novavax's COVID shot. The updated vaccine is authorized for use in individuals 12 ...
A phase I clinical trial was carried out to evaluate the safety and immunogenicity of the vaccine candidate in about 360 participants. [4] The phase II concluded in April 2021. [12] [13] [14] In April 2021, the Drugs Controller General of India permitted the vaccine candidate to start phase III clinical trials. A total of 1,268 healthy ...